Home / abpnews home / Indanlatestnews / Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

नवंबर 11, 2021 abpnews home, Indanlatestnews

Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

कोई टिप्पणी नहीं

सदस्यता लें टिप्पणियाँ भेजें ( Atom )